Literature DB >> 8923319

Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery.

R A Rajewski1, V J Stella.   

Abstract

The objective of this Review is to summarize and critique recent findings and applications of both unmodified and modified cyclodextrins for in vivo drug delivery. This review focuses on the use of cyclodextrins for parenteral, oral, ophthalmic, and nasal drug delivery. Other routes including dermal, rectal, and pulmonary delivery are also briefly addressed. This Review primarily focuses on newer findings concerning cyclodextrin derivatives which are likely to receive regulatory acceptance due to improved aqueous solubility and safety profiles as compared to the unmodified cyclodextrins. Many of the applications reviewed involve the use of hydroxypropyl-beta-cyclodextrins (HP-beta-CDs) and sulfobutylether-beta-cyclodextrins (SBE-beta-CDs) which show promise of greater safety while maintaining the ability to form inclusion complexes. The advantages and limitations of HP-beta-CD, SBE-beta-CD, and other cyclodextrins are addressed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8923319     DOI: 10.1021/js960075u

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  75 in total

1.  Enhanced solubility, stability, and transcorneal permeability of δ-8-tetrahydrocannabinol in the presence of cyclodextrins.

Authors:  Ketan Hippalgaonkar; Waseem Gul; Mahmoud A ElSohly; Michael A Repka; Soumyajit Majumdar
Journal:  AAPS PharmSciTech       Date:  2011-06-03       Impact factor: 3.246

Review 2.  Solubilizing excipients in oral and injectable formulations.

Authors:  Robert G Strickley
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

Review 3.  The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs.

Authors:  Arik Dahan; Jonathan M Miller
Journal:  AAPS J       Date:  2012-03-06       Impact factor: 4.009

4.  Antitumour efficacy of two paclitaxel formulations for hyperthermic intraperitoneal chemotherapy (HIPEC) in an in vivo rat model.

Authors:  Wim Bouquet; Steven Deleye; Steven Staelens; Lieselotte De Smet; Nancy Van Damme; Isabelle Debergh; Wim P Ceelen; Filip De Vos; Jean Paul Remon; Chris Vervaet
Journal:  Pharm Res       Date:  2011-03-18       Impact factor: 4.200

Review 5.  Carrier-based strategies for targeting protein and peptide drugs to the lungs.

Authors:  Sally-Ann Cryan
Journal:  AAPS J       Date:  2005-03-24       Impact factor: 4.009

Review 6.  Past, present, and future technologies for oral delivery of therapeutic proteins.

Authors:  Rajesh Singh; Shailesh Singh; James W Lillard
Journal:  J Pharm Sci       Date:  2008-07       Impact factor: 3.534

7.  Synthesis of a Disulfonated Derivative of Cucurbit[7]uril and Investigations of its Ability to Solubilize Insoluble Drugs.

Authors:  Elizabeth L Robinson; Peter Y Zavalij; Lyle Isaacs
Journal:  Supramol Chem       Date:  2015-05-01       Impact factor: 1.688

Review 8.  Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease.

Authors:  Elizabeth A Ottinger; Mark L Kao; Nuria Carrillo-Carrasco; Nicole Yanjanin; Roopa Kanakatti Shankar; Marjo Janssen; Marcus Brewster; Ilona Scott; Xin Xu; Jim Cradock; Pramod Terse; Seameen J Dehdashti; Juan Marugan; Wei Zheng; Lili Portilla; Alan Hubbs; William J Pavan; John Heiss; Charles H Vite; Steven U Walkley; Daniel S Ory; Steven A Silber; Forbes D Porter; Christopher P Austin; John C McKew
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

9.  2-Hydroxypropyl-β-cyclodextrin promotes transcription factor EB-mediated activation of autophagy: implications for therapy.

Authors:  Wensi Song; Fan Wang; Parisa Lotfi; Marco Sardiello; Laura Segatori
Journal:  J Biol Chem       Date:  2014-02-20       Impact factor: 5.157

10.  Carbopol-based gels for nasal delivery of progesterone.

Authors:  Grace Rathnam; N Narayanan; R Ilavarasan
Journal:  AAPS PharmSciTech       Date:  2008-10-11       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.